To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
Trial details
- Registry ID
- NCT05908084
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Human Acellular Vessel (HAV)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084 | HUMA | Phase 3 | Active not recruiting | 2027-06Estimated |
| Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418 | HUMA | Phase 2, Phase 3 | Completed | 2023-09-19Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |